Free Trial

Apellis Pharmaceuticals (APLS) Stock Forecast & Price Target

Apellis Pharmaceuticals logo
$27.43 -0.70 (-2.49%)
As of 11:51 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Apellis Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
9
Buy
10

Based on 19 Wall Street analysts who have issued ratings for Apellis Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 9 have given a hold rating, 9 have given a buy rating, and 1 has given a strong buy rating for APLS.

Consensus Price Target

$34.12
24.39% Upside
According to the 19 analysts' twelve-month price targets for Apellis Pharmaceuticals, the average price target is $34.12. The highest price target for APLS is $57.00, while the lowest price target for APLS is $19.00. The average price target represents a forecasted upside of 24.39% from the current price of $27.43.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for APLS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Apellis Pharmaceuticals and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

APLS Analyst Ratings Over Time

TypeCurrent Forecast
9/8/24 to 9/8/25
1 Month Ago
8/9/24 to 8/9/25
3 Months Ago
6/10/24 to 6/10/25
1 Year Ago
9/9/23 to 9/8/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
9 Buy rating(s)
10 Buy rating(s)
11 Buy rating(s)
10 Buy rating(s)
Hold
9 Hold rating(s)
9 Hold rating(s)
9 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$34.12$36.83$40.05$72.13
Forecasted Upside24.39% Upside51.14% Upside104.56% Upside75.72% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

APLS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

APLS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Apellis Pharmaceuticals Stock vs. The Competition

TypeApellis PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.58
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside23.70% Upside16,476.70% Upside10.76% Upside
News Sentiment Rating
Positive News

See Recent APLS News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
8/4/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Anupam Rama
1 of 5 stars
Boost TargetOverweight$35.00 ➝ $37.00+52.51%
8/1/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lisa Walter
Not Rated
Boost TargetSector Perform$17.00 ➝ $19.00-17.58%
8/1/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Steve Seedhouse
Not Rated
Boost TargetOverweight$39.00 ➝ $40.00+71.92%
8/1/2025Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$52.00 ➝ $50.00+121.17%
7/29/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$41.00 ➝ $46.00+148.70%
7/18/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$47.00 ➝ $50.00+149.50%
7/16/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$23.00 ➝ $24.00+24.03%
7/2/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$25.00 ➝ $26.00+42.46%
6/2/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$26.00 ➝ $29.00+50.94%
5/14/2025Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetNeutral$30.00 ➝ $20.00+18.65%
5/8/2025Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetSector Perform$28.00 ➝ $20.00+14.35%
5/7/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$40.00 ➝ $29.00+63.13%
3/3/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetNeutral$36.00 ➝ $32.00+29.05%
3/3/2025Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetNeutral$30.00 ➝ $29.00+15.31%
3/3/2025HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$57.00 ➝ $57.00+126.64%
11/6/2024Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetNeutral$40.00 ➝ $32.00+13.98%
11/6/2024Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetOutperform$65.00 ➝ $40.00+42.48%
10/31/2024Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
10/16/2024William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
8/9/2024UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$85.00 ➝ $83.00+119.34%
7/31/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy$80.00 ➝ $80.00+100.20%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 11:52 AM ET.


APLS Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Apellis Pharmaceuticals is $34.12, with a high forecast of $57.00 and a low forecast of $19.00.

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 9 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" APLS shares.

According to analysts, Apellis Pharmaceuticals's stock has a predicted upside of 24.39% based on their 12-month stock forecasts.

Apellis Pharmaceuticals has been rated by research analysts at Bank of America, Cantor Fitzgerald, Citigroup, JPMorgan Chase & Co., Morgan Stanley, Raymond James Financial, Robert W. Baird, and Royal Bank Of Canada in the past 90 days.

Analysts like Apellis Pharmaceuticals less than other "medical" companies. The consensus rating score for Apellis Pharmaceuticals is 2.58 while the average consensus rating score for "medical" companies is 2.78. Learn more on how APLS compares to other companies.


This page (NASDAQ:APLS) was last updated on 9/8/2025 by MarketBeat.com Staff
From Our Partners